TLR9 and graft versus host disease: The administration of CpG ODNs at the time of Allo-HSCT accelerates GvHD in a host APC-TLR9-dependent manner and a host IFN-γ-dependent manner, but independent of host IL-6, IL-12, or natural killer (NK) cells (71).